Literature DB >> 2101599

Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis.

M Y Choy1, J A Walker-Smith, C B Williams, T T MacDonald.   

Abstract

Many interleukin-2 receptor (CD25) bearing cells can be identified by alkaline phosphatase immunohistochemistry in the diseased intestinal lamina propria of children with Crohn's disease or ulcerative colitis, but rarely in normal intestine. In both diseases, the CD25+ cells are present as aggregates in the lamina propria below the epithelium, and constitute a large proportion of the lamina propria mononuclear cells. In Crohn's disease, but not ulcerative colitis, CD25+ cells are abundant in the submucosa. The CD25+ cells in Crohn's disease are 58-88% CD3+, CD4+, CD8-, indicating that they are T cells, whereas in ulcerative colitis the CD25+ cells are greater than 80% CD3-, CD4+, HLA-DR+, indicating that they are macrophages. Thus, differential expression of CD25 on T cells and macrophages serves to distinguish the immunologic lesions in ulcerative colitis and Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2101599      PMCID: PMC1378758          DOI: 10.1136/gut.31.12.1365

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis.

Authors:  H E LOCKHART-MUMMERY; B C MORSON
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

2.  The pathology of regional enteritis.

Authors:  H RAPPAPORT; F H BURGOYNE; H F SMETANA
Journal:  Mil Surg       Date:  1951-10

3.  Changes in intraepithelial lymphocyte subpopulations in coeliac disease and enteropathy associated T cell lymphoma (malignant histiocytosis of the intestine).

Authors:  J Spencer; T T MacDonald; T C Diss; J A Walker-Smith; P J Ciclitira; P G Isaacson
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

4.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.

Authors:  Y R Mahida; K Wu; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

5.  Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease.

Authors:  C A Seldenrijk; H A Drexhage; S G Meuwissen; S T Pals; C J Meijer
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

6.  Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum.

Authors:  Y R Mahida; S Patel; P Gionchetti; D Vaux; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

7.  Stimulation of mucosal T cells in situ with anti-CD3 antibody: location of the activated T cells and their distribution within the mucosal micro-environment.

Authors:  T Monk; J Spencer; N Cerf-Bensussan; T T MacDonald
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

8.  Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease.

Authors:  M C Allison; S Cornwall; L W Poulter; A P Dhillon; R E Pounder
Journal:  Gut       Date:  1988-11       Impact factor: 23.059

9.  HLA-DR expression in human fetal intestinal epithelium.

Authors:  T T MacDonald; A Weinel; J Spencer
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

10.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

View more
  45 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

3.  CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.

Authors:  A Stronkhorst; S Radema; S L Yong; H Bijl; I J ten Berge; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

4.  Activation of lamina propria T cells induces crypt epithelial proliferation and goblet cell depletion in cultured human fetal colon.

Authors:  C M Evans; A D Phillips; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

5.  Interleukin-2 receptor expression.

Authors:  Y R Mahida
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

6.  T cell receptor V beta expression by mucosal T cells.

Authors:  J Spencer; M Y Choy; T T MacDonald
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

7.  Flow cytometric analysis of expression of transforming growth factor-beta and glucocorticoid-induced tumor necrosis factor receptor on CD4(+) CD25(+) T cells of patients with inflammatory bowel disease.

Authors:  Maho Ikeda; Fuminao Takeshima; Kazuo Ohba; Ken Ohnita; Hajime Isomoto; Masaki Yamakawa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 8.  Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.

Authors:  J P Ibbotson; J R Lowes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

9.  Enhanced absorption of macromolecules. A secondary factor in Crohn's disease.

Authors:  M Malin; E Isolauri; P Pikkarainen; R Karikoski; J Isolauri
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

10.  An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.

Authors:  D G Forcione; B Sands; K J Isselbacher; A Rustgi; D K Podolsky; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.